UNSPSC 51332854: Fluphenazine sulfoxide

This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7V73CQS9VA, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-10h-phenothiazin-10-yl)propyl)-, s-oxide, but more generally known as fluphenazine sulfoxide, which bears US NIH Compound Identifier 3036919. European Medicines Agency schedules fluphenazine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07730MIG.

Most nations, for tariff purposes, schedule fluphenazine sulfoxide under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3[S+]2[O-])C(F)(F)F)CCCN4CCN(CC4)CCO.

UNSPSC 51332854 Fluphenazine sulfoxide is a Commodity code that in recent state and local solicitations appears to represent pharmaceutical products more broadly than its narrow chemical name suggests — state and local procurement offices are using this code to tag requests for naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products that support community health, emergency response, and pharmacy benefit programs. The issuing bodies soliciting under the code span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). Procurement vehicles include traditional competitive bidding (IFB), exploratory information-gathering (RFI), and formal request-for-proposal processes (RFP) with multi-year terms and renewal options.

Recent activity is concentrated in Texas, Florida, and Minnesota-led regional purchasing consortia. Seminole County's IFB 60459723LAS, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023 (note: this deadline date appears inconsistent with the posting date and may reflect a data error in the source). Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, explored vendor capacity to establish direct-to-manufacturer prescription programs for self-insured employee and state health plans, indicating early-stage demand for alternative pharmaceutical sourcing models. Minnesota's MMCAP RFP S1070000015802, posted January 20, 2026, with responses due March 26, 2026, established multiple contracts for generic pharmaceuticals and OTC products across participating states and local facilities, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), maintain cGMP and DSCSA compliance, carry $5 million commercial general liability insurance per occurrence, and accept a 3 percent administrative fee on all contract purchases.